Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10146, NNC0487-0111 B 10144
NovoThirteen
Obesity
1 trial -
NNC0487-0111 B 10142, Placebo (NNC0487-0111), NNC0487-0111 B 10143, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10141
NovoThirteen
HFpEF or HFmrEF and obesity
1 trial -
NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141
NovoThirteen
Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure
1 trial -
NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10142, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10144, NNC0487-0111 B 10141
NovoThirteen
Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)
1 trial -
NNC0487-0111 B 10146, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10141
NovoThirteen
Obesity
1 trial -
NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10145, NNC0487-0111 B 10144
NovoThirteen
Overweight or obesity, and type 2 diabetes
1 trial -
NP101
Teva Pharma GmbH
Migraine Disorders
2 trials -
NP101 Sumatriptan Iontophoretic Transdermal Patch
Teva Pharma GmbH
Migraine Disorders
2 trials -
NTLA-2001
Regeneron UK Limited
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
1 trial -
NUBEQA 300 mg film-coated tablets, Placebo to BAY1841788 film-coated tablet 300 mg
Ningbo Cancer Hospital
Localised Very High-Risk Cancer of the Prostate
1 trial -
NaCl 0,9 % B. Braun, solution injectable, Depo-Medrone 40 mg/ml Suspension for Injection.
Disc Medicine
Cluster headache
1 trial -
NaCl 0.9%, PREDNISONE ARROW 20 mg, comprimé sécable, METHYLPREDNISOLONE , Placebo de prednisone ARW 20 mg - Hydrogénophosphate de calcium dihydraté (94%) Stéarate de magnésium (1%) Amidon de maïs Lycatab C (5%), Glucose 5%
Pari Pharma GmbH
Erythema multiforme (EM) in its severe form managed at the hospital
1 trial -
NaCl 0.9%, TRANEXAMIC ACID, TERLIPRESSIN
Pari Pharma GmbH
Hemoptysis, whatever the cause, with the exception of cystic fibrosis
1 trial -
Nabiximols
Jazz Pharmaceuticals Ireland Limited
Spasticity in Participants With Multiple Sclerosis
1 trial -
Nabiximols
Jazz Pharmaceuticals Ireland Limited
Pain
3 trials -
Nabiximols
Jazz Pharmaceuticals Ireland Limited
Multiple Sclerosis (MS)
1 trial -
Nabiximols
Jazz Pharmaceuticals Ireland Limited
Post-Traumatic Stress Disorder
1 trial -
Nabiximols
Jazz Pharmaceuticals Ireland Limited
Spasticity With Multiple Sclerosis
1 trial -
Nacubactam, Imipenem/Cilastatin Kabi 500 mg/500 mg Pulver zur Herstellung einer Infusionslösung, Cefepim PANPHARMA 2 g Pulver zur Herstellung einer Injektions- bzw. Infusionslösung, AZACTAM 1 g, poudre et solution pour usage parentéral
Lacuna Pharma Pty Ltd
Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)
1 trial -
Nadroparin, long term
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
Namodenoson
Can-Fite BioPharma
Hepatocellular Carcinoma
1 trial -
Nano-crystalline Megestrol Acetate Oral Suspension
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
Nanocovax
Biotech Pharmaceutical Co.,
SARS-CoV-2 Infection
1 trial -
Napabucasin, Bendatax 6 mg/ ml, Bendacitabin 38 mg/ml Pulver zur Herstellung einer Infusionslösung
The George Institute
Histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is metastatic.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources